SCP Vitalife Partners

Investment decisions are driven by founder and chairman Morris Kahn alongside managing partner Ittai Harel. The team maintains a concentrated partnership structure, with a small group of investment professionals possessing clinical and engineering backgrounds evaluating each opportunity. The firm operates with the long-duration timeline characteristic of single-family-anchored venture capital.

SCP Vitalife sits within the Shalam Capital Partners (SCP) group, Morris Kahn's private investment platform. Kahn's wealth originated from founding Amdocs, the telecom billing and customer-experience software company that listed on the NYSE in 1998. His investment group also includes technology ventures and substantial philanthropic initiatives — notably the Beresheet lunar mission and marine research at the Morris Kahn Marine Research Station — but SCP Vitalife operates as a dedicated, ring-fenced healthtech venture franchise.

The firm concentrates on medical devices and digital health, with a historical portfolio spanning cardiovascular devices, ophthalmology, neurology, and surgical robotics. It enters at the earliest institutional stage — leading seed and Series A rounds — and works with portfolio companies through the FDA or CE-mark approval process and subsequent commercial-scale ramp-up. The firm has historically favored capital-efficient, hardware-plus-software medical device models over biotech or drug-discovery platforms.

The firm's highest-profile exit is Given Imaging, the capsule endoscopy company that pioneered non-invasive visualization of the gastrointestinal tract. Given was acquired by Covidien (now Medtronic) for roughly $860 million in 2013. Another portfolio company, Optonol, which developed minimally invasive glaucoma drainage implants, was acquired by Alcon. These exits established the firm's track record of bridging Israeli biomedical engineering with global acquirers.

While the firm is headquartered in Tel Aviv and overwhelmingly sources its deals from Israel's medical-technology research ecosystem, it pursues commercial pathways and syndicate partnerships internationally — particularly in the United States, where portfolio companies typically seek FDA clearance and first-revenue contracts. The firm has not historically operated satellite offices in other markets, concentrating partner time on the tight Israeli healthtech cluster.